Visão geral da empresa
A biotechnology enterprise dedicated to the development and commercialization of therapeutic solutions specifically targeting urothelial and specialty cancers. UroGen Pharma Ltd. operates within the broader Healthcare sector, specifically classified under the Biotechnology industry, which implies a focus on high-risk, high-reward research and development phases rather than mature manufacturing operations. The company maintains a market capitalization of $929.83M, supported by annual revenue of $109.79M and an operational workforce of 291 employees. These valuation figures indicate that the market assigns significant capital weight to the company's proprietary assets and potential future commercialization of its pipeline, particularly its novel RTGel technology and generic drug offerings, despite the absence of current profitability.
Saúde financeira
The company reported a trailing twelve-month revenue of $109.79M, while simultaneously posting a net income of $-153,494,000 and an EBITDA of $-124,556,000. The substantial gap between positive revenue and negative net income reveals a cost structure characterized by heavy operating expenses, likely driven by research and development costs inherent to biotechnology firms in the pre-profitability stage. Free cash flow stands at $-99,423,000, indicating that current operations are consuming cash reserves rather than generating liquidity, which limits immediate financial flexibility for external expansion. The gross margin is reported at 88.7%, suggesting high efficiency in the cost of goods sold relative to sales, while the operating margin of -50.5% and profit margin of -139.8% reflect the intense burn rate required to fund innovation before achieving commercial scale. Regarding liquidity, the company holds $120.46M in cash against $130.09M in debt, resulting in a debt-to-equity ratio that is not applicable due to the company's capitalization structure. The current ratio of 4.01 indicates a robust short-term liquidity position, where current assets significantly exceed current liabilities, providing a buffer against short-term obligations. Return on Equity is not applicable, and the return on assets stands at -32.1%, which reveals that for every dollar of assets employed, the company generates a negative return, a typical characteristic of growth-stage biotech companies reinvesting heavily in their operations.
Avaliação de valorização
The trailing P/E ratio is not applicable given the lack of earnings, whereas the forward P/E is 20.70, implying that the market is pricing in anticipated future profitability rather than current historical performance. The price-to-book ratio is -8.76, a negative figure that indicates the market is valuing the company at a discount to its book value, often seen in firms with significant intangible assets or where asset values do not fully capture the value of the intellectual property pipeline. Alternative valuation metrics such as the price-to-sales ratio of 8.47 and the EV/EBITDA of -7.54 suggest that investors are willing to pay a premium for the revenue base, anticipating that future earnings will eventually align with current sales multiples. The stock has traded between a 52-week high of $30.00 and a low of $3.42, and without a specific current price listed in the data, the valuation context relies on these historical extremes to define the potential upside or downside range from the recent trading floor. With a beta of 1.44, the stock exhibits price volatility that is significantly higher than the broader market, suggesting that the asset class moves with greater amplitude than the S&P 500, reflecting the high risk profile associated with small-cap biotechnology equities.
Growth & Income
Revenue growth year-over-year is 54.0%, while earnings growth is not applicable due to the company's current unprofitable status, indicating that top-line expansion is occurring without corresponding bottom-line improvement. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, meaning that all available earnings are theoretically retained, though in this specific case, the company is burning cash to fund its growth initiatives rather than distributing income. This reinvestment strategy is typical for biotechnology firms in the development phase, where capital is directed toward clinical trials and regulatory approval rather than shareholder returns. The overall growth and income profile is defined by aggressive top-line expansion coupled with a complete lack of dividend income, positioning the investment purely for potential capital appreciation based on the successful commercialization of its urothelial cancer solutions.